AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chemomab's Nebokitug Shows Favorable Safety, Consistent Biomarker Improvements in PSC Patients
ByAinvest
Thursday, Nov 6, 2025 8:04 am ET1min read
Chemomab Therapeutics announced new clinical data from its nebokitug Phase 2 SPRING trial in primary sclerosing cholangitis (PSC). The data shows favorable safety and consistent improvements in key biomarkers in PSC patients treated with nebokitug for up to 48 weeks. The presentations have been designated as posters of distinction and will be presented at AASLD The Liver Meeting 2025 on November 10, 2025.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Incβs editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
ο»Ώ
No comments yet